Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAN-2409 + Valacyclovir in Malignant Glioma
NCT00589875Phase 2Completed
- Sponsor
- Candel Therapeutics
- Start
- Mar 2007
- Primary completion
- Dec 2015
- Modality
- Gene Editing, Gene Silencing, Oncolytic Viruses
- Countries
- 1
01
Overview
A Phase 2 trial of aglatimagene besadenovec in malignant glioma, sponsored by Candel Therapeutics. Started Mar 2007; status: completed.
02
Drugs
aglatimagene besadenovec
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00589875.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00589875.